Onpattro (Generic Patisiran): Complete Medication Guide
Key Takeaways
Generic patisiran treats transthyretin (TTR) amyloidosis, a rare genetic disorder affecting nerves and the heart
Administered as an intravenous infusion every 3 weeks to slow disease progression
Common side effects include infusion reactions, nausea, and fatigue; serious risks include heart problems and liver issues
Generic vs Brand Name Drugs can offer substantial cost savings while maintaining the same active ingredient
Requires regular monitoring through blood tests and heart function assessments during treatment
Onpattro (Generic Patisiran) Overview
Onpattro (patisiran) is a groundbreaking RNA interference therapeutic used to treat transthyretin (TTR) amyloidosis, a rare and serious genetic disorder. This medication works by silencing the TTR gene, reducing the production of abnormal transthyretin protein that accumulates in nerves and organs—particularly the heart—causing progressive damage. TTR amyloidosis can lead to severe neuropathy (nerve damage), cardiomyopathy (heart disease), and organ failure if left untreated.
The generic version of patisiran contains the same active pharmaceutical ingredient as the brand-name Onpattro, making it a Cost-Effective Alternative to Brand-Name Drugs for patients with this life-limiting condition. The medication is delivered intravenously, allowing direct access to the bloodstream for maximum therapeutic effect. Patisiran has been shown to slow the progression of polyneuropathy in TTR amyloidosis patients, helping preserve nerve function and quality of life.
TTR amyloidosis comes in two forms: hereditary (hATTR) and wild-type (wtATTR). The hereditary form runs in families and typically appears earlier in life, while wild-type amyloidosis primarily affects older men. Both forms benefit from patisiran therapy. Understanding your specific type of amyloidosis and disease stage is essential for determining whether this medication is right for you—discuss your individual situation with your healthcare provider.
This information is educational and does not replace advice from your healthcare provider.
Side Effects
Patisiran is generally well-tolerated, though infusion-related reactions and other side effects are possible. Most side effects are manageable with proper monitoring and medical support. Your doctor will discuss how to recognize and report any concerning symptoms.
Common Side Effects
Infusion reactions — Fever, chills, nausea, vomiting, or flushing during or shortly after infusion; usually mild and managed with pre-medication
Nausea and vomiting — May occur during infusion or within hours afterward; generally resolves within 24 hours
Fatigue — Tiredness or weakness lasting a few days after each infusion
Headache — Ranging from mild to moderate, typically resolving within 48 hours
Joint or muscle pain — Temporary discomfort similar to flu-like symptoms
Decreased appetite — Mild reduction in hunger lasting a day or two after treatment
Serious Side Effects
Severe infusion reactions — Anaphylaxis, severe bronchospasm, or cardiovascular collapse requiring immediate medical intervention
Heart arrhythmias or heart failure — Worsening of existing cardiac amyloidosis with abnormal heart rhythms or reduced pump function
Liver injury — Elevated liver enzymes or hepatotoxicity, though rare with patisiran
Thrombocytopenia — Low platelet counts increasing bleeding and bruising risk
Peripheral edema and fluid retention — Swelling in legs and ankles, particularly in patients with cardiac involvement
When to Seek Medical Attention
Contact your healthcare provider immediately if you experience difficulty breathing, severe chest pain, fainting, rapid or irregular heartbeat, severe allergic reactions, yellowing of skin or eyes, unusual bleeding or bruising, or severe swelling. These symptoms may indicate serious complications requiring urgent evaluation. Additionally, call your doctor if you develop persistent nausea, vomiting preventing food intake, severe fatigue preventing daily activities, or new neurological symptoms such as numbness, tingling, or weakness. Never wait until your next scheduled appointment if you suspect a serious side effect—prompt medical attention can prevent complications.
Dosage
Dose Level or Form |
Dose |
Key Detail |
Standard IV Infusion |
0.3 mg/kg body weight |
Administered intravenously over 80 minutes every 3 weeks |
Maximum Single Dose |
30 mg per infusion |
Dose capped regardless of body weight for safety |
Premedication Protocol |
Anti-inflammatory + antihistamine |
Given 60 minutes before infusion to reduce reaction risk |
Treatment Duration |
Ongoing, long-term |
Typically continued indefinitely or until disease progression or intolerance |
Important: Do not stop patisiran without consulting your doctor, as discontinuation may allow disease progression to resume. If you miss an infusion appointment, reschedule as soon as possible—do not double doses or compress the schedule without medical guidance. Always inform healthcare providers administering the infusion about any new medications, supplements, or health changes since your last dose, as these may affect safety or efficacy.
Drug Interactions
Patisiran has relatively few direct drug-drug interactions due to its RNA interference mechanism, but certain medications and supplements may affect tolerability or treatment outcomes. Always inform your medical team about all medications and supplements you take.
Anticoagulants and Antiplatelet Agents
Blood thinners like warfarin or aspirin may increase bleeding risk if patisiran causes thrombocytopenia. Monitor platelet counts closely and discuss bleeding precautions with your doctor.
Hepatotoxic Medications
Drugs that stress the liver (such as acetaminophen at high doses, certain antibiotics, or anticonvulsants) may compound patisiran's rare hepatic effects. Minimize use of such medications when possible.
NSAIDs and Pain Relievers
High-dose nonsteroidal anti-inflammatory drugs can reduce platelet function and increase GI bleeding risk, especially if patisiran lowers platelet counts. Use acetaminophen or other alternatives when appropriate.
Corticosteroids and Immunosuppressants
These medications may mask or worsen infusion reactions or affect immune response. Coordinate use with your treating physician to optimize safety.
Herbal Supplements
Ginkgo biloba, garlic, ginger, and other blood-thinning supplements may increase bleeding risk in combination with patisiran-related thrombocytopenia. Discuss all supplements before starting treatment.
Continue Learning
Related articles you might find helpful
Pros and Cons
Pros
Slows disease progression — Proven to slow polyneuropathy progression in TTR amyloidosis, preserving nerve function and quality of life
Addresses root cause — Targets the genetic source of disease by silencing TTR gene expression, not just managing symptoms
Convenient dosing schedule — Once-every-3-weeks infusion allows patients to plan around treatment rather than daily pills
Generic option available — Generic vs Brand Name Drugs contain identical active ingredients, reducing out-of-pocket costs significantly
Established safety profile — Years of clinical use and ongoing monitoring have well-characterized tolerability patterns
Cons
Infusion-dependent delivery — Requires visiting a healthcare facility every 3 weeks; no home-based oral alternative
Potential for serious infusion reactions — Anaphylaxis and severe reactions, though rare, carry life-threatening risks
Requires pre-medication — Must take corticosteroids, antihistamines, and antipyretics 60 minutes before each infusion
Ongoing monitoring burden — Requires regular blood tests and heart function assessments throughout treatment
High cost even as generic — Remains expensive; insurance coverage varies, and patient assistance programs may be necessary
Frequently Asked Questions
Get answers to common questions about generic patisiran (Onpattro).
Generic patisiran contains the same active pharmaceutical ingredient at identical strength and potency as brand-name Onpattro. Both are manufactured to strict FDA standards. The main difference is price—generics typically cost significantly less. Save Money on Generic Drugs for High blood pressure and cholesterol may apply similar savings principles. Your insurance plan determines coverage and out-of-pocket costs.
Patisiran slows disease progression by reducing transthyretin protein production, but it does not reverse existing nerve damage. Early treatment offers the best outcomes because it prevents further deterioration while some nerve function remains intact. Starting therapy before extensive damage occurs maximizes benefit. Discuss your disease stage and prognosis with your neurologist.
Contact your doctor immediately to reschedule. Missing one infusion will not cause a crisis, but delaying treatment allows disease progression to resume. Do not attempt to "catch up" by scheduling infusions closer together or increasing the dose. Stick to the regular 3-week schedule as closely as possible for optimal disease control.
Yes. Other options for TTR amyloidosis include tafamidis (Vyndaqel), which stabilizes transthyretin protein, and diflunisal, which also provides stabilization. Some patients benefit from liver transplantation in early hereditary TTR amyloidosis. Discuss alternative treatments with your healthcare team if patisiran causes unacceptable side effects.
TTR amyloidosis is a progressive genetic disorder, so patisiran is typically continued indefinitely to maintain disease control. Stopping the medication allows amyloidosis progression to resume. Your doctor will periodically reassess whether continued treatment remains beneficial and safe, but discontinuation is rarely recommended unless serious complications develop or new treatments become available.
The Bottom Line
Generic patisiran (Onpattro) represents a breakthrough therapy for transthyretin amyloidosis, a rare genetic disorder that progressively damages nerves and the heart. By silencing the TTR gene, this medication slows disease progression and preserves quality of life when started early. While infusion reactions and monitoring requirements exist, the proven benefits for eligible patients make patisiran a cornerstone treatment. Generic vs. Brand-Name Drugs offer identical effectiveness at lower cost, making this critical therapy more accessible. If you have TTR amyloidosis or suspect you might, talk with your neurologist or amyloidosis specialist about whether patisiran is right for you.
Ready to take control of your health? Get started with Doctronic today—our AI-powered platform provides 24/7 access to medical guidance. Doctronic, the first AI legally authorized to practice medicine, has delivered over 22 million consultations with 99.2% treatment alignment with physicians. Get free AI consultations or affordable video ($39) and text ($19) visits with real doctors—average wait time is just 4 minutes. All services are HIPAA compliant and anonymous by default.
